Application Note | April 2, 2024
Cell Surface Proteomics for ADC Development: Deep Profiling of TAAs
Get the Resource
Download NowAntibody-drug conjugates (ADCs) are a promising new class of cancer therapeutics. They offer a powerful combination of specificity and potency via targeted delivery of cytotoxic agents to tumor cells. The antibody component of the ADC selectively recognizes and binds to tumor-associated antigens (TAAs) on the tumor cell surface, allowing the drug payload to be delivered directly into the cancer cell.
The optimization of ADC-target binding is critical to achieve necessary efficacy while mitigating off-target effects. Comprehensive characterization of cell surface TAAs is therefore among the most important criteria in developing ADC therapies.
Cell surface proteomics to advance ADCs as precision medicines
The cell surface proteome serves as a rich source of potential therapeutic targets for ADCs. Explore how Sapient’s /Deep/ Cell Surface Proteomics approach enables comprehensive measure of up to 1,000 well defined cell surface proteins. You’ll learn how this approach is used to identify TAAs that are differentially and abundantly expressed on tumors compared to healthy tissues, enabling selection of the optimal targets.
Download the Application Note to explore the technical details of our method for cell surface proteomics, and how it can be applied to advance ADC development through the identification and characterization of TAAs, including discovery of novel TAAs for ADC targeting.
Key differentiators of our cell surface proteomics method
Our workflow is enabled by Evosep liquid chromatography coupled to Bruker timsTOF HT mass spectrometers. With these instruments we are able to achieve deep proteome coverage and high confidence identification of proteins and PTMs.
Sapient performs global proteomic experiments or can selectively enrich cell surface proteins to screen different cell lines, tissues, and tumors. Importantly, our workflow provides information on the abundance of 1,000 surface proteins as well as informs on their copy numbers. Quantification of protein copy numbers within and across indications helps to nominate TAAs as attractive targets for ADC development.
Through deep surface protein profiling and quantitative insights, our platform empowers informed decision-making in TAA selection. Ultimately, our cell surface proteomics data drives the optimization of ADCs for enhanced efficacy and safety in cancer therapy.
